[Ip-health] Cato event w/Public Citizen Thursday: Patents, Public Health, and International Law: The Eli Lilly Nafta Chapter 11 Case

Peter Maybarduk pmaybarduk at citizen.org
Fri Jan 10 09:37:29 PST 2014


The Cato Institute invites you to an event.

View this email in your browser<http://us1.campaign-archive2.com/?u=98c97f42691d5de57bc944822&id=5400c95697&e=cab9764f64>





[http://gallery.mailchimp.com/98c97f42691d5de57bc944822/images/cato_dark_177.jpg]

The Cato Institute invites you to a Policy Forum
Thursday, January 16, 2014




Patents, Public Health, and International
Law: The Eli Lilly NAFTA Chapter 11 Case<http://cato.us1.list-manage.com/track/click?u=98c97f42691d5de57bc944822&id=c7605e85d4&e=cab9764f64>

featuring
Burcu Kilic
Legal Counsel, Public Citizen Global Access to Medicine Program

Christopher Sands
Senior Fellow, Hudson Institute

and
Mark Schultz
Associate Professor, Southern Illinois University School of Law, and Senior Scholar,
Center for the Protection of Intellectual Property, George Mason University School of
Law

moderated by
Simon Lester
Trade Policy Analyst, Herbert A. Stiefel Center for Trade Policy Studies,
Cato Institute

In recent years, controversy has arisen over perceived conflicts between intellectual property protection and public health, and also over the role of international investment rules that allow corporations to sue governments before international tribunals. A new case combines both issues. Pharmaceutical company Eli Lilly has filed a claim before a NAFTA tribunal, alleging that Canadian court decisions in response to challenges from the Canadian generic drug industry have unfairly invalidated some of the company's Canadian patents. Eli Lilly has asked for CDN$500 million as compensation for the damages it has suffered. This forum assembles experts with different perspectives on the case to sort through the various intellectual property, public health, and international law issues involved: Is the "promise utility" doctrine relied on by the Canadian courts credible? Is public health undermined or helped by this shift, which will favor the generic drug industry? Is it appropriate for international tribunals to play a role here? Please join us for a spirited discussion.






Policy Forum
Thursday, January 16, 2014, 2013, 11:00 a.m.

Cato Institute, 1000 Massachusetts Ave., N.W., Washington, D.C. 20001.

To register to attend this event, click the button below and then submit the form on the page that opens, or email events at cato.org<mailto:events%40cato.org>, fax (202) 371-0841, or call (202) 789-5229 by 11:00 a.m. on Wednesday, January 15, 2014.

[http://gallery.mailchimp.com/98c97f42691d5de57bc944822/images/register_black_77x26.jpg]<http://cato.us1.list-manage.com/track/click?u=98c97f42691d5de57bc944822&id=8cd52a7fa1&e=cab9764f64>




If you can't make it to the Cato Institute, watch this event live online at www.cato.org/live<http://cato.us1.list-manage.com/track/click?u=98c97f42691d5de57bc944822&id=7b53f83109&e=cab9764f64> and follow @CatoEvents<http://cato.us1.list-manage1.com/track/click?u=98c97f42691d5de57bc944822&id=58e029d6b3&e=cab9764f64> on Twitter to get future event updates, live streams, and videos from the Cato Institute.















More information about the Ip-health mailing list